IFN-α-ELP(V) can be slowly released from the drug reservoir, exhibits zero-order release kinetics, considerably improves pharmacokinetics and biodistribution, penetrates surrounding brain tissue, stimulates local antitumor immune responses, and can prevent recurrence of GBM (Fig. 4A) [49]. The gene discussed is IFNA1; the disease is glioblastoma.